Flo Health is a London-based fertility-focused period-tracking app offering cycle and ovulation tracking, symptom monitoring (users can track over 70 symptoms), and personalized health insights. The company says it has served some 380 million users globally, with about 70 million monthly active users on its free product and roughly 5 million paid subscribers. Flo monetizes through premium subscriptions and intends to keep subscriptions as its core business model. The company plans to expand features for perimenopause and menopause, continue integrations with devices like Apple Watch, and may pursue acquisitions to grow inorganically. Flo highlights its privacy and security posture, noting a settled 2021 FTC investigation and dual ISO certifications (ISO 27001 and ISO 27701). Founded in 2015 by Dmitry Gurski and his twin brother, Flo operates from London with a major hub in Vilnius and runs a pro-social program that provides free premium access in 66 countries, benefiting nearly 16 million women. Flo Health, Inc. announced it received $49.704991 million in funding. The investment was provided by VNV Global AB and Target Germanium GmbH. The transaction closed on September 9, 2021. The Series B round was led by Target Germanium GmbH and included new investor VNV Global AB (publ). The funding was raised at a post-money valuation of $800,000,000. The article does not disclose operating metrics, product details, or future plans. Flo Health is a Belarusian women's health app with broad reach: about 10% of women aged 15–40 in Europe and the US use Flo. The company introduced monetization in early 2019 and says it doubled active audience year-over-year with average monthly revenue growth of 30%. Flo is described as the most popular and commercially successful product in its category. Today the company employs 140 specialists in the CIS and plans to grow headcount to 200 by year-end. Management says investments will be directed at further product development and team growth. Following the extension, Flo's valuation rose to $230 million. Flo Health develops Flo, a women's health product that combines a neural-network-based period and ovulation calendar, a personalized content feed, and anonymous social/group chat functionality. The app targets females across life stages (menstruation start, cycle tracking, conception, pregnancy, early motherhood, menopause) and emphasizes safety and trusted health information. Flo makes intensive use of data science and AI to deliver personalized content and services and is available in 22 languages on iOS and Android. Launched in October 2015, the app has been downloaded over 70 million times and reports 28 million monthly users; the user base grows by about 4.5 million downloads monthly. Flo is the number one female health product by active audience in the U.S. (per App Annie) and has sizable penetration in over 100 countries, with 60% of users in the U.S. and Europe. Company leadership cites ambitions to scale further and leverage investor partnerships for product and market expansion across Asian, European, and American markets. Flo Health develops Flo, an AI-driven women's health app that provides cycle tracking, conception preparation, pregnancy support, early motherhood tools and menopause care. Since its October 2015 launch the app has been downloaded over 60 million times and records 22 million monthly active users, with installs growing by about 4.5 million per month. Over 4 million women have become pregnant using Flo, a figure that the company says is increasing by roughly 500,000 per month. Flo uses neural networks and proprietary AI algorithms to improve cycle predictions, detect concerning symptoms, and deliver personalized guidance and prompts to seek medical care. The company employs 100+ specialists (around 70% women), offers the tracker in 22 languages, and reports roughly 60% of users are in the US and Europe. Flo aims to reach 100 million monthly active users, build a large anonymous women's community, and expand scientific and research partnerships to advance personalization and medical credibility.

Total raised

$276M

Funding rounds

7

Latest round

Series C

Latest activity

Jul 2024